{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:42:18Z","timestamp":1778665338437,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3543-7","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T13:51:45Z","timestamp":1503496305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-1250","authenticated-orcid":false,"given":"Monika","family":"Sztankay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes Maria","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"August","family":"Zabernigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Krempler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Pall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hilbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Burghuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Doering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Holzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"3543_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"3543_CR2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2016.0031","volume":"14","author":"DS Ettinger","year":"2016","unstructured":"Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D\u2019Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Cancer Netw. 2016;14:255\u201364.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3543_CR3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40265-013-0032-4","volume":"73","author":"EM Berge","year":"2013","unstructured":"Berge EM, Doebele RC. Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs. 2013;73:517\u201332.","journal-title":"Drugs"},{"issue":"Electronic Supp","key":"3543_CR4","doi-asserted-by":"crossref","first-page":"eS46","DOI":"10.3949\/ccjm.78.s2.10","volume":"79","author":"NA Pennell","year":"2012","unstructured":"Pennell NA. Selection of chemotherapy for patients with advanced non-small cell lung cancer. Cleve Clin J Med. 2012;79(Electronic Suppl 1):eS46\u201350.","journal-title":"Cleve Clin J Med"},{"key":"3543_CR5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","volume":"31","author":"DE Gerber","year":"2013","unstructured":"Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013;31:1009\u201320.","journal-title":"J Clin Oncol"},{"key":"3543_CR6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lungcan.2011.10.021","volume":"76","author":"J Treat","year":"2012","unstructured":"Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer. 2012;76:222\u20137.","journal-title":"Lung Cancer"},{"key":"3543_CR7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jtho.2016.03.007","volume":"11","author":"S Kulkarni","year":"2016","unstructured":"Kulkarni S, Vella ET, Coakley N, Cheng S, Gregg R, Ung YC, Ellis PM. The use of systemic treatment in the maintenance of patients with non-small cell lung cancer: a systematic review. J Thorac Oncol. 2016;11:989\u20131002.","journal-title":"J Thorac Oncol"},{"key":"3543_CR8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/1471-2407-12-423","volume":"12","author":"N Mubarak","year":"2012","unstructured":"Mubarak N, Gaafar R, Shehata S, Hashem T, Abigeres D, Azim HA, El-Husseiny G, Al-Husaini H, Liu Z. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer. 2012;12:423.","journal-title":"BMC Cancer"},{"key":"3543_CR9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1758834013510589","volume":"6","author":"RD Gentzler","year":"2014","unstructured":"Gentzler RD, Patel JD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2014;6:4\u201315.","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 3","key":"3543_CR10","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","volume":"25","author":"M Reck","year":"2014","unstructured":"Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27\u201339.","journal-title":"Ann Oncol"},{"key":"3543_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247\u201355.","journal-title":"Lancet Oncol"},{"key":"3543_CR12","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","volume":"374","author":"T Ciuleanu","year":"2009","unstructured":"Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432\u201340.","journal-title":"Lancet"},{"key":"3543_CR13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(11)70339-4","volume":"13","author":"CP Belani","year":"2012","unstructured":"Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13:292\u20139.","journal-title":"Lancet Oncol"},{"key":"3543_CR14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cllc.2014.06.007","volume":"15","author":"JL Pujol","year":"2014","unstructured":"Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2014;15:418\u201325.","journal-title":"Clin Lung Cancer"},{"key":"3543_CR15","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ejca.2012.11.006","volume":"49","author":"E Juhasz","year":"2013","unstructured":"Juhasz E, Kim JH, Klingelschmitt G, Walzer S. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer. 2013;49:1205\u201315.","journal-title":"Eur J Cancer"},{"key":"3543_CR16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdr125","volume":"23","author":"B Coudert","year":"2012","unstructured":"Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, Cappuzzo F. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol. 2012;23:388\u201394.","journal-title":"Ann Oncol"},{"key":"3543_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2012.45.4553","volume":"31","author":"JM Unger","year":"2013","unstructured":"Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31:536\u201342.","journal-title":"J Clin Oncol"},{"key":"3543_CR18","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.pctr.0010009","volume":"1","author":"PM Rothwell","year":"2006","unstructured":"Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1:e9.","journal-title":"PLoS Clin Trials"},{"key":"3543_CR19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3816\/CLC.2008.n.030","volume":"9","author":"DF Cella","year":"2008","unstructured":"Cella DF, Patel JD. Improving health-related quality of life in non-small-cell lung cancer with current treatment options. Clin Lung Cancer. 2008;9:206\u201312.","journal-title":"Clin Lung Cancer"},{"key":"3543_CR20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1470-2045(11)70398-9","volume":"13","author":"TE Stinchcombe","year":"2012","unstructured":"Stinchcombe TE, Cella D. Does maintenance pemetrexed maintain quality of life? Lancet Oncol. 2012;13:224\u20135.","journal-title":"Lancet Oncol"},{"key":"3543_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"3543_CR22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","volume":"69","author":"JM Giesinger","year":"2016","unstructured":"Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, Sprangers MA, Velikova G, Aaronson NK. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79\u201388.","journal-title":"J Clin Epidemiol"},{"key":"3543_CR23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","volume":"30A","author":"B Bergman","year":"1994","unstructured":"Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life. Eur J Cancer. 1994;30A:635\u201342.","journal-title":"Eur J Cancer"},{"key":"3543_CR24","unstructured":"Group EQoL. Item Library In."},{"key":"3543_CR25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1472-6947-12-126","volume":"12","author":"B Holzner","year":"2012","unstructured":"Holzner B, Giesinger JM, Pinggera J, Zugal S, Schopf F, Oberguggenberger AS, Gamper EM, Zabernigg A, Weber B, Rumpold G. The computer-based health evaluation software (CHES): a software for electronic patient-reported outcome monitoring. BMC Med Inform Decis Mak. 2012;12:126.","journal-title":"BMC Med Inform Decis Mak"},{"key":"3543_CR26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pec.2012.04.013","volume":"89","author":"DE Gerber","year":"2012","unstructured":"Gerber DE, Hamann HA, Rasco DW, Woodruff S, Lee SJ. Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. Patient Educ Couns. 2012;89:102\u20138.","journal-title":"Patient Educ Couns"},{"key":"3543_CR27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/JTO.0b013e31825879ea","volume":"7","author":"L Peeters","year":"2012","unstructured":"Peeters L, Sibille A, Anrys B, Oyen C, Dooms C, Nackaerts K, Wauters I, Vansteenkiste J. Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients\u2019 perceptions. J Thorac Oncol. 2012;7:1291\u20135.","journal-title":"J Thorac Oncol"},{"key":"3543_CR28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lungcan.2012.01.016","volume":"77","author":"JF Bridges","year":"2012","unstructured":"Bridges JF, Mohamed AF, Finnern HW, Woehl A, Hauber AB. Patients\u2019 preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012;77:224\u201331.","journal-title":"Lung Cancer"},{"key":"3543_CR29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865\u20139.","journal-title":"N Engl J Med"},{"key":"3543_CR30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/bjs.8989","volume":"100","author":"RC Macefield","year":"2013","unstructured":"Macefield RC, Avery KN, Blazeby JM. Integration of clinical and patient-reported outcomes in surgical oncology. Br J Surg. 2013;100:28\u201337.","journal-title":"Br J Surg"},{"key":"3543_CR31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/pon.3087","volume":"22","author":"CF Snyder","year":"2013","unstructured":"Snyder CF, Blackford AL, Wolff AC, Carducci MA, Herman JM, Wu AW. Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice. Psychooncology. 2013;22:895\u2013901.","journal-title":"Psychooncology"},{"key":"3543_CR32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00259-015-3022-9","volume":"42","author":"EM Gamper","year":"2015","unstructured":"Gamper EM, Wintner LM, Rodrigues M, Buxbaum S, Nilica B, Singer S, Giesinger JM, Holzner B, Virgolini I. Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme. Eur J Nucl Med Mol Imaging. 2015;42:1179\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3543_CR33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","volume":"22","author":"G Velikova","year":"2004","unstructured":"Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22:714\u201324.","journal-title":"J Clin Oncol"},{"key":"3543_CR34","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.ejca.2010.04.030","volume":"46","author":"G Velikova","year":"2010","unstructured":"Velikova G, Keding A, Harley C, Cocks K, Booth L, Smith AB, Wright P, Selby PJ, Brown JM. Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer. 2010;46:2381\u20138.","journal-title":"Eur J Cancer"},{"key":"3543_CR35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(11)60459-5","volume":"377","author":"I Haines","year":"2011","unstructured":"Haines I. Rituximab maintenance therapy for follicular lymphoma. Lancet. 2011;377:1151. author reply 1151-1152","journal-title":"Lancet"},{"key":"3543_CR36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-010-0925-9","volume":"122","author":"CG Murphy","year":"2010","unstructured":"Murphy CG, Khasraw M, Seidman AD. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2010;122:177\u20139.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T03:23:39Z","timestamp":1602818619000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3543-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3543"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3543-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]},"article-number":"565"}}